Key Highlights

  • Neumora Therapeutics, Inc. (NASDAQ:NMRA) rose about 7.9% in early trading on Monday, October 26, 2026, near USD 0.41, and the company has not issued a release explaining the move.
  • On Monday, June 15, 2026 the company reported that navacaprant missed its primary endpoint in two Phase 3 studies, and the shares closed about 48.6% lower that day.
  • It ended the navacaprant programme, cut about 35% of staff, and guided to annual savings of about USD 10 million and a cash runway into the third quarter of 2027.
  • The remaining pipeline includes NMRA-511 for Alzheimer's disease agitation, NMRA-898 for schizophrenia and NMRA-215 for obesity, each with milestones due by the end of 2026.

A Rebound on No News, Below USD 1.00

Neumora Therapeutics, Inc. (NASDAQ:NMRA) is a clinical-stage neuroscience company. Its shares rose about 7.9% in early trading on Monday, October 26, 2026, with prices described as intraday and near USD 0.41. The company has not issued a release explaining the move. The shares remain far below levels before Monday, June 15, 2026, when the company reported results from the Phase 3 KOASTAL programme. Navacaprant, taken at 80 mg, changed depression scores by 12.2 points against 12.0 for placebo in KOASTAL-2, and by 10.1 against 10.8 in KOASTAL-3, so both primary and key secondary endpoints were missed. The shares closed about 48.6% lower that day.

How the Restructuring Reshapes the Company

After the failure, Neumora Therapeutics, Inc. (NASDAQ:NMRA) discontinued navacaprant and reduced its workforce by about 35%. It expects annualised savings of about USD 10 million against one-time costs of about USD 2 million, and a cash runway into the third quarter of 2027 including clinical milestones. The value now rests on three earlier programmes. NMRA-511, a vasopressin V1a receptor antagonist, is due to complete a multiple ascending dose cohort in healthy elderly volunteers in the fourth quarter of 2026 and to start a Phase 2b study by year end. NMRA-898, an M4 modulator for schizophrenia, has Phase 1 data due in the second half of 2026. NMRA-215, an NLRP3 inhibitor, targets obesity and cardiometabolic disease.

Risks and What to Watch

The first risk for Neumora Therapeutics, Inc. (NASDAQ:NMRA) is listing status: a price near USD 0.41 sits below the USD 1.00 minimum bid requirement of the exchange, which can lead to a deficiency notice and later a reverse split. The second is funding, since a runway into the third quarter of 2027 may require new capital before the pipeline produces value. The third is clinical risk across the three remaining programmes. Early moves in a stock that has fallen sharply often reflect trading, not news. Investors should watch the NMRA-898 Phase 1 data due in the second half of 2026, the NMRA-511 milestones in the fourth quarter, third-quarter results and the Federal Reserve decision on Wednesday, October 28, 2026.

Where Things Stand

The answer is that Neumora Therapeutics, Inc. (NASDAQ:NMRA) rose about 7.9% in early trading without a company release, in a rebound from levels set by the failure of navacaprant on Monday, June 15, 2026. The restructuring extends the cash runway into the third quarter of 2027, and the pipeline has several milestones before year end. The next catalysts are the Phase 1 data for NMRA-898, the NMRA-511 study start and the Federal Reserve decision on Wednesday, October 28, 2026. Clinical results are uncertain, early gains can reverse, and this is not investment advice.